The number of people with Alzheimer’s disease (AD) is skyrocketing, and better diagnostic tools and potential new treatments are boosting the global AD market. AD is a brain disorder that worsens over time and mainly affects people over 65. It leads to the gradual breakdown of brain cells, causing memory loss, trouble thinking, and problems with daily activities. Symptoms of AD include dementia (Mental illnesses), confusion, repetitive actions, restlessness, anxiety, depression, sleep problems, and more. Currently, there is no way to prevent, cure, or stop the disease, which affects over 55 million people worldwide. Treatments only offer temporary and minor improvements in symptoms, and no approved drugs can slow the disease’s progression. The many affected people and the lack of effective treatments create a significant opportunity for new solutions.
According to the Alzheimer’s Association, over 55 million people worldwide live with dementia, with Alzheimer’s disease accounting for 60-70% of cases. By 2050, this number is expected to triple, underscoring the urgency for effective treatments and early diagnostic tools.
The global market for Alzheimer’s Disease therapeutics and diagnostics, valued at $9.7 billion in 2024, is forecast to surpass $19.6 billion by 2029, reflecting a five-year compound annual growth rate (CAGR) of 15.1%. Market growth is driven by the increasing proportion of the population with AD, growing awareness, higher diagnostic rates, and improved access to treatment and public funding.